Supplemental Table 1 from Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts

Key Points

• MAIN FINDING: Nanobody-directed CAR T cells demonstrate efficacy in eliminating gastrointestinal cancer xenografts.
• KEY EVIDENCE: Clinical trials show significant tumor reduction in patients with CEA-positive solid tumors.
• APPROACH: The study conducted a review of various clinical trials involving CEA-targeted CAR T-cell therapies.
• SIGNIFICANCE: These findings provide new insights into targeted cancer therapies, enhancing treatment strategies for solid tumors.